Precision BioSciences reports $108.5M preliminary cash; receives $2.5M from TG Therapeutics, issues shares

PRECISION BIOSCIENCES INC

Preliminary unaudited cash, cash equivalents, and restricted cash of ~$108.5M as of Dec 31, 2024, before $2.5M TG payment in Jan 2025.
Expects cash runway into second half of 2026, sufficient to fund two wholly owned programs through Phase 1 data readouts.
On Jan 6, 2025, received $2.5M deferred cash payment from TG Subsidiary and issued 220,712 shares of common stock.
The payment and shares relate to the January 2024 License Agreement for non-oncology applications of allogeneic CAR T therapy azer-cel.
These estimates are preliminary and subject to audit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.